FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016006304> ?p ?o ?g. }

• W2016006304 endingPage "217" @default.
• W2016006304 startingPage "209" @default.
• W2016006304 abstract "AimTo assess docetaxel–estramustine in patients with localised high-risk prostate cancer.Patients and methodsAfter staging pelvic lymph node dissection, patients with high-risk prostate cancer randomly received androgen deprivation therapy (ADT) (3 years) + DE (4 cycles of docetaxel 70 mg/m2/3 weeks + estramustine 10 mg/kg/d d1–5) or ADT alone. Local therapy was administered at 3 months.ResultsFour hundred and thirteen patients were accrued: T3–T4 (67%), Gleason score ⩾8 (42%), PSA >20 ng/mL (59%), pN+ (29%). In the chemotherapy arm, 94% of patients received the planned four cycles of docetaxel. Local treatment consisted of radiotherapy in 358 patients (87%) (median dose 74 Gy in both arms). ADT was given for 36 months in both arms. A PSA response (PSA ⩽0.2 ng/mL after 3 months of treatment) was obtained in 34% and 15% in the ADT + DE arm and in the ADT arm, respectively (p < 0.0001). Febrile neutropenia occurred in only 2%. Moderate to severe hot flashes occurred less often in the ADT + DE arm (2% versus 22%; p < 0.001). There was no toxicity-related death, no secondary leukaemia, and no excess second cancers. Chemotherapy had a negative impact on quality of life (global health status, p = 0.01; fatigue, p = 0.003; role functioning, p = 0.003; social functioning, p = 0.006) at 3 months but this effect disappeared at 1 year.ConclusionDocetaxel–estramustine can be combined safely with standard therapy in high-risk prostate cancer, with a promising PSA response rate and no negative impact on quality of life after 1 year. Long-term follow-up is required to assess the impact on relapse and survival." @default.
• W2016006304 created "2016-06-24" @default.
• W2016006304 creator A5001456598 @default.
• W2016006304 creator A5007779528 @default.
• W2016006304 creator A5011506675 @default.
• W2016006304 creator A5013166168 @default.
• W2016006304 creator A5016485718 @default.
• W2016006304 creator A5021549650 @default.
• W2016006304 creator A5026180389 @default.
• W2016006304 creator A5026462289 @default.
• W2016006304 creator A5031054777 @default.
• W2016006304 creator A5032656430 @default.
• W2016006304 creator A5032686530 @default.
• W2016006304 creator A5033220136 @default.
• W2016006304 creator A5034922000 @default.
• W2016006304 creator A5035784239 @default.
• W2016006304 creator A5040479101 @default.
• W2016006304 creator A5040832651 @default.
• W2016006304 creator A5041283530 @default.
• W2016006304 creator A5043616693 @default.
• W2016006304 creator A5046909112 @default.
• W2016006304 creator A5047019507 @default.
• W2016006304 creator A5049406196 @default.
• W2016006304 creator A5049633907 @default.
• W2016006304 creator A5057183350 @default.
• W2016006304 creator A5065732872 @default.
• W2016006304 creator A5067036952 @default.
• W2016006304 creator A5073913050 @default.
• W2016006304 creator A5081051779 @default.
• W2016006304 creator A5083891313 @default.
• W2016006304 date "2012-01-01" @default.
• W2016006304 modified "2023-10-16" @default.
• W2016006304 title "A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial" @default.
• W2016006304 cites W1510099181 @default.
• W2016006304 cites W1853704205 @default.
• W2016006304 cites W1971541628 @default.
• W2016006304 cites W1984994876 @default.
• W2016006304 cites W1985587689 @default.
• W2016006304 cites W1996809772 @default.
• W2016006304 cites W2005419234 @default.
• W2016006304 cites W2019368518 @default.
• W2016006304 cites W2021220421 @default.
• W2016006304 cites W2039960040 @default.
• W2016006304 cites W2054899405 @default.
• W2016006304 cites W2066944903 @default.
• W2016006304 cites W2073253608 @default.
• W2016006304 cites W2074421032 @default.
• W2016006304 cites W2080439368 @default.
• W2016006304 cites W2087567089 @default.
• W2016006304 cites W2096602429 @default.
• W2016006304 cites W2097532477 @default.
• W2016006304 cites W2099324760 @default.
• W2016006304 cites W2101995865 @default.
• W2016006304 cites W2106285196 @default.
• W2016006304 cites W2117204935 @default.
• W2016006304 cites W2117511763 @default.
• W2016006304 cites W2118792538 @default.
• W2016006304 cites W2120292596 @default.
• W2016006304 cites W2120398882 @default.
• W2016006304 cites W2123526148 @default.
• W2016006304 cites W2127900847 @default.
• W2016006304 cites W2131809909 @default.
• W2016006304 cites W2134766389 @default.
• W2016006304 cites W2141283971 @default.
• W2016006304 cites W2142359566 @default.
• W2016006304 cites W2144312415 @default.
• W2016006304 cites W2145300558 @default.
• W2016006304 cites W2148386014 @default.
• W2016006304 cites W2148539277 @default.
• W2016006304 cites W2149696900 @default.
• W2016006304 cites W2151698969 @default.
• W2016006304 cites W2164194457 @default.
• W2016006304 cites W2165109497 @default.
• W2016006304 cites W2178139012 @default.
• W2016006304 doi "https://doi.org/10.1016/j.ejca.2011.10.015" @default.
• W2016006304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22119204" @default.
• W2016006304 hasPublicationYear "2012" @default.
• W2016006304 type Work @default.
• W2016006304 sameAs 2016006304 @default.
• W2016006304 citedByCount "47" @default.
• W2016006304 countsByYear W20160063042012 @default.
• W2016006304 countsByYear W20160063042013 @default.
• W2016006304 countsByYear W20160063042014 @default.
• W2016006304 countsByYear W20160063042015 @default.
• W2016006304 countsByYear W20160063042016 @default.
• W2016006304 countsByYear W20160063042017 @default.
• W2016006304 countsByYear W20160063042018 @default.
• W2016006304 countsByYear W20160063042019 @default.
• W2016006304 countsByYear W20160063042020 @default.
• W2016006304 countsByYear W20160063042021 @default.
• W2016006304 countsByYear W20160063042022 @default.
• W2016006304 countsByYear W20160063042023 @default.
• W2016006304 crossrefType "journal-article" @default.
• W2016006304 hasAuthorship W2016006304A5001456598 @default.
• W2016006304 hasAuthorship W2016006304A5007779528 @default.
• W2016006304 hasAuthorship W2016006304A5011506675 @default.
• W2016006304 hasAuthorship W2016006304A5013166168 @default.
• W2016006304 hasAuthorship W2016006304A5016485718 @default.

• next